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ISSNIntroduction: The risk of adverse drug events associated with nevirapine (NVP) is
suggested to be greater in pregnant women. We conducted a systematic review and
meta-analysis of severe adverse events in HIV-positive womenwho initiated NVPwhile
pregnant.
Methods: We searched six databases for studies reporting adverse events among HIV-
positive pregnant women who had received NVP-based antiretroviral therapy for at
least 7 days. Data were pooled by the fixed-effects method.
Results: Twenty studies (3582 pregnant women) from 14 countries were included in the
final review. The pooled proportion of patients experiencing a severe hepatotoxic event
was 3.2% [95% confidence interval (CI) 2.1–4.3%], severe rash was experienced by
3.3% of patients (95% CI 2.1–4.5%) and 6.1% (95% CI 3.9–8.3%) of patients
discontinued NVP due to an adverse event. These results were comparable to fre-
quencies observed in the general adult patient population, and to frequencies reported
in non-pregnant women within the same cohort. For pregnant women with a CD4 cell
count above 250 cells/ml there was a non-significant tendency towards an increased
likelihood of severe cutaneous adverse events (OR 1.4, 95% CI 0.8–2.4) and severe
hepatotoxic events (OR 1.5, 95%CI 0.9-2.3) and consequently an increased risk of
toxicity-driven regimen substitution (OR 1.7, 95% CI 1.1–2.6).
Discussion: These results suggest that the frequency of adverse events associated with
NVP use in pregnant women, although high, is no higher than reported for NVP in the
general adult population. Pregnant women with a high CD4 cell count may be at
increased risk of adverse events, but evidence supporting this association is weak.
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Current WHO guidelines for antiretroviral therapy
(ART) recommend using either nevirapine (NVP) or
efavirenz as part of combination ART [1]. NVP has
been preferred for the treatment of HIV-positive
pregnant women because of concerns about efavirenz
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Co
1136 AIDS 2013, Vol 27 No 7In resource-limited settings, NVP continues to be
extensively used in pregnancy, both as part of ART for
treatment-eligible women and for prophylaxis for
prevention of mother-to-child transmission (PMTCT)
of HIV. Current WHO guidelines for provision of
antiretrovirals to pregnant women for both treatment and
PMTCTurge caution in the use of NVP in women with
CD4 cell counts of between 250 and 350 cells/ml, and
recommend against the use of NVP at CD4 cell count
above 350 cells/ml or in those women with unknown
CD4 cell counts. These guidelines do, however,
recognize that the benefits of using NVP in pregnancy
in these circumstances can outweigh the risks of not
initiating ART [6].
In order to help inform the revision of the 2013 WHO
guidelines for ART, and given current considerations to
extend access to ART regardless of CD4 cell count for all
pregnant women for life [7], we conducted a systematic
review andmeta-analysis of adverse events inHIV-positive
pregnant women initiating antiretroviral treatment includ-
ing NVP, and reviewed the association between the
occurrence of adverse events and CD4 cell count.Methods
This systematic review and meta-analysis was conducted
according to the criteria of the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses group [8].
Eligibility criteria
We initially sought randomized trials and prospective
cohorts reporting adverse events among HIV-positive
women who initiated NVP while pregnant. Anticipating
a relative paucity of information, we also included
retrospective cohorts as part of our search strategy.
According to our predefined eligibility criteria (see
protocol in Web Appendix), studies had to report
outcomes among treatment-naı¨ve women who initiated
NVP while pregnant and had received NVP-based
therapy for at least 7 days, either for their own health or as
part of combination prophylaxis for PMTCT. Studies that
included women who had initiated NVP preconcep-
tionally or reported adverse events that occurred after
delivery were excluded.
Search strategy and study selection
The following databases were searched from inception to
1 October 2012: MEDLINE via PubMed, EMBASE,
LILACS, Web of Science, Current Controlled Trials, and
the Cochrane database of systematic reviews. We also
reviewed conference abstracts from the International
AIDS Society conferences from July 2009 to July 2012 to
identify potential studies that were recently completed
but have not yet been published as full-text articles.
Finally, bibliographies of relevant articles were screened.
No date, geographical, or language restriction was applied.pyright © Lippincott Williams & Wilkins. UnauthoPublished articles identified by our search strategy were
screened by one reviewer (N.F.), and the abstracts of
potentially eligible studies were then assessed indepen-
dently and in duplicate (N.F., Z.S.) to select potentially
relevant full-text articles. Once a preliminary selection of
articles was made, a list of these studies was sent to experts
in the field to try to identify additional studies. Final
agreement on study inclusions was determined through
consensus (A.C., I.A.M., N.F. and Z.S.).
Data extraction
We conducted data extraction independently, in dupli-
cate, using a standardized data extraction form (N.F.,
Z.S.). Once agreement was reached, completed data
extraction forms were sent to authors of each study for
verification and to seek additional data not reported by
the published articles. We sought data on the number of
pregnant women receiving NVP who experienced
hepatotoxicity, rash or hypersensitivity reaction, which
was defined as severe hepatotoxicity and/or severe rash
(provided sufficient information was available to avoid
double counting of patients). These adverse events were
classified as mild/moderate or severe according to severity
grading as defined by the studies; hepatic or cutaneous
events that resulted in discontinuation of NVP were
considered severe. When reported by the studies, the
number of adverse events was disaggregated in order
to compare outcomes among pregnant versus non-
pregnant women, and pregnant women with CD4 cell
count 250 cells/ml or less versus CD4 cell count above
250 cells/ml. Frequencies of adverse events in pregnant
women receiving NVP were also compared against
frequencies of adverse events for NVP in adults in general,
basedondata froma recent systematic reviewconductedby
the same researchers [9]. Secondary outcomes included the
number of any adverse events resulting in treatment
discontinuation, termination of pregnancy due to adverse
events, and mortality associated with adverse events.
Data on patient and study characteristics, monitoring
strategies and adverse event classification used, and relevant
indicators of potential risks of bias were also extracted. The
quality of the evidence for each primary outcome was
assessed using the Grading of Recommendations Assess-
ment, Development, and Evaluation (GRADE) system
[10].
Data analysis
We calculated point estimates and 95% confidence
intervals (95% CIs) for the proportion of patients
experiencing each outcome using the Freeman Tukey
approach [11]. The odds ratios (ORs), risk differences,
and the corresponding 95% CIs for each outcome were
calculated, applying the Haldane method in the event of
zero outcomes in one arm [12], and data were pooled
using a fixed-effects model [13]. Data from randomized
trials and prospective cohorts were analysed together as no
important differences have been found between designsrized reproduction of this article is prohibited.
Adverse events associated with nevirapine use in pregnancy Ford et al. 1137in the reliability of reporting of adverse events [14].
Heterogeneity was assessed using the I2 statistic [15].
Recognizing that the I2 statistic provides large estimates
of heterogeneity when evaluating proportions, we
examined the following predefined subgroups to explore
heterogeneity within our primary outcomes of rash and/
or hepatitis as a result of NVP: study design (prospective
versus retrospective), level of economic development of
the study setting (low or lower-middle income country
versus middle or high-income country, as defined by the
World Bank; http://data.worldbank.org/about/country-
classifications/country-and-lending-groups), gestational
age at initiation of NVP (third trimester versus earlier)
and concomitant use of other drugs associated with the
outcomes of interest (rifampicin, co-trimoxazole or
isoniazid).
All analyses were conducted using Stata version 12.0
(StataCorp. LP, College Station, Texas, USA) and
GRADE Pro (www.gradeworkinggroup.org).Results
Study inclusions
After an initial review of 1031 titles, 411 abstracts were
screened, 61 articles were assessed in full (Fig. 1) and
agreement was reached on the inclusion of 20 studies.Copyright © Lippincott Williams & Wilkins. Unaut
1031titles screened
85 Medline
326 Embase
314 Web of science
9 Lilacs
73 controlled trials
224 IAS abstracts 
411 abstracts screened
57 articles screened
4 articles included from
bibliographies  
20 studies included in th
final review  
Fig. 1. Flow diagram of study selection process.These studies comprised two randomized trials [2,4], five
prospective cohorts [3,5,16–18] and 13 retrospective
cohorts [19–31], and reported data from 14 countries
including five countries in Africa, two countries in Latin
America, one country in Asia, with the remainder carried
out in Western (high income) settings. Most studies (10)
used the United States Division of AIDS grading system
for severity of adverse events. In all, 3582 women who
initiated NVP while pregnant were included in this
review. Study characteristics are summarized in Table 1
and monitoring strategies are detailed in Supplementary
Table S1, http://links.lww.com/QAD/A300. Authors of
16 studies confirmed data extractions and provided
additional data [3–5,16–19,21,22–24,25,27,30–32].
Assessment of methodological quality
Overall risk of bias for studies included in this review was
considered to be moderate to high. The majority of
studies were observational, and most (13) were retro-
spective in design. Few studies reported on potential
confounding factors or attempted to adjust for these at
baseline or analysis (Supplementary Table S2, http://
links.lww.com/QAD/A300). The GRADE assessment
for risk of adverse events comparing high and low CD4
cell counts rated the quality of evidence as being very low
for all outcomes, mainly due to serious imprecision and
risk of bias (Supplementary Table S3, http://links.lww.
com/QAD/A300).horized reproduction of this article is prohibited.
 
e
620 excluded
354 excluded 
-   8 duplicate reports
-   11 studies did not report adverse
     event data
-   6 studies only used single-dose
     nevirapine
-   10 studies did not provide
     disaggregated data
-   1 study did not report denominator
-   5 studies did not report outcomes
     for pregnant women 
41 excluded after full text review for one
or more of the following reasons:
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Adverse events associated with nevirapine use in pregnancy Ford et al. 1139Frequency and risk of adverse events
Across all 20 studies, the pooled proportion of pregnant
women experiencing a hepatotoxic event was 6.8% (95%
CI 4.6–9.0%); the proportion of patients experiencing a
severe hepatotoxic event was 3.2% (95% CI 2.1–4.3%).
Rash was experienced by 7.2% of patients (95% CI 5.6–
8.9%); severe rash was experienced by 3.2% of patients
(95% CI 2.1–4.3%); hypersensitivity reaction was
experienced by 6.5% of patients (95% CI 4.3–8.6%).
Overall, 6.1% (95%CI 3.9–8.3%) of patients discontinued
NVP due to NVP-associated adverse events. Mortality
associated with adverse events was low, with four deaths
reported attributed to NVP-associated adverse events:
three deaths were reported from two retrospective
cohorts [26,27] and the final death was reported from
a prospective cohort [2]. All four deaths occurred among
patients with a pretreatment CD4 cell count of more than
250 cells/ml.
In subgroup analyses, a higher proportion of hepatotoxic
events was reported in prospective studies (8.9%, 95% CI
4.0–13.9%) compared to retrospective studies (5.8%, 95%
CI 3.3–8.4%), and in studies in which the median
gestational age at ART initiation was during the third
trimester of pregnancy (8.5%, 95% CI 3.4–13.6%)Copyright © Lippincott Williams & Wilkins. Unaut
Hepatotoxicity: general
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0
Fig. 2. Pooled proportion of adverse events comparing pregnantcompared to the first/second trimester (4.3%, 95% CI
1.6–7.0%). No other differences were observed.
We compared the frequency of adverse events among
pregnant women included in this systematic review with
the frequency of adverse events associated with NVP use
in the general adult population reported by another
recent systematic review using similar methodology [9].
These comparisons, which are summarized in Fig. 2,
suggest that there are no differences in the frequencies of
adverse events comparing pregnant women to HIV-
positive adults overall.
Adverse events according to CD4 cell count
among pregnant women
Fifteen studies reported data on outcomes comparing
pregnantwomenwith a lowerCD4cell count (250 cells/
ml) and a higher CD4 cell count (>250 cells/ml) [2–5,16–
19,22–25,27,28,31]. For women with a CD4 cell count
greater than 250 cells/ml there was a non-significant
tendency towards an increased likelihood of cutaneous
events overall (OR1.1, 95%CI 0.8–1.6), severe cutaneous
adverse events (OR 1.4, 95% CI 0.8–2.4) and con-
sequently an increased risk of toxicity-driven regimen
substitution (OR 1.7, 95% CI 1.1–2.6). The likelihood ofhorized reproduction of this article is prohibited.
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Fig. 3. Pooled odds ratio for severe rash by CD4 cell count.severe cutaneous events was higher in prospective studies,
although this was still non-significant (OR 1.6, 95% CI
0.8–3.0). Overall, no difference in the likelihood of
hepatotoxic events was seen, but a greater risk of severe
hepatic events was found when the analysis was restricted
to prospective studies (OR 3.9, 95% CI 1.6–9.5) (Figs. 3
and 4).
Adverse events according to pregnancy status
Six studies reported adverse event data from cohorts that
included both treatment-naive pregnant and non-
pregnant women [5,17,19,20,22,29]. Among these
studies, there was no evidence of an increased likelihood
of developing any adverse outcome. The ORs for adverse
events comparing pregnant and non-pregnant women
were all non-significant: hepatotoxicity 1.3 (95% CI 0.8–
1.9); severe hepatotoxicity 1.4 (95% CI 0.9–2.1); rash 1.2
(95% CI 0.8–1.9); severe rash 0.8 (95% CI 0.5–1.4);
hypersensitivity 0.7 (95% CI 0.5–1.0). Discontinuations
were not assessed, as this outcome was considered to be at
high risk of bias (because of current concern regarding
increased risk of NVP-associated adverse events in
pregnant women and heightened concern about safetypyright © Lippincott Williams & Wilkins. Unauthoin pregnancy, treatment was more likely to be discon-
tinued in pregnant women compared to non-pregnant
women).Discussion
Nevirapine is one of the most widely used antiretroviral
drugs included in first-line triple ART, particularly in
low- and middle-income countries. All antiretroviral
drugs carry a risk of toxicity, and in the case of NVP a
higher risk of hepatotoxicity and rash has been
documented compared to efavirenz, the common non-
nucleoside reverse transcriptase inhibitor alternative
to NVP.
The risk of adverse events associated with NVP, in
particular hepatic and cutaneous events, has been
considered to be high in pregnant women generally,
and in particular for those with a high CD4 cell count.
Clinical guidelines have reflected this concern by advising
NVP use only with careful toxicity monitoring andrized reproduction of this article is prohibited.
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Fig. 4. Pooled odds ratio for severe hepatotoxicity by CD4 cell count.recommending against the use of NVP in pregnant
women with CD4 cell count above 350 cells/ml [6]. This
has led to complex algorithms, particularly for PMTCT
[6]. Efavirenz has recently been recommended by WHO
as the preferred first-line option [33], but assessment of
risk for NVP is still important since it remains widely used
and is recommended as an alternative to efavirenz.
This systematic review found no evidence of increased
risk of NVP-related adverse events associated with
pregnancy compared to non-pregnant adults, and only
weak evidence of elevated risk of cutaneous and hepatic
events among pregnant women initiating a NVP-based
ART at higher CD4 cell count. Nevertheless, the
frequency of occurrence of adverse events was generally
high, with almost 1 in 10 pregnant women experiencing a
hepatotoxic event in prospective studies.
A recent systematic review specifically assessed the
question of NVP safety in pregnancy according to
CD4 cell counts, and concluded that there was a
significantly higher risk of severe events at CD4 cell count
above 250 cells/ml [34]. Our review differs from this
review in several ways. First, our definition of severe
adverse events included any grade of adverse event that
resulted in a drug discontinuation. Second, we excluded
data on patients in whom adverse events were reportedCopyright © Lippincott Williams & Wilkins. Unautafter delivery (some studies followed up patients for up to
6 months after delivery). Finally, we were able to obtain
additional information and clarifications from authors of
three-quarters of all included studies, which allowed the
inclusion of additional studies in the CD4 analysis.
There are several strengths and limitations to note. We
used a broad search strategy that identified a number of
published and unpublished studies, and included
additional data provided by authors. We paid particular
attention to data verification, extracting all outcome data
independently, in duplicate, and verifying data with study
authors. However, the overall meta-analysis dataset was
small for some outcomes which may have limited the
possibility to detect a difference for certain analyses. Some
of the analyses presented in this review are based on
retrospective data, which carry a higher risk of bias
resulting in a possible over-estimation or under-
estimation of events in these studies. We chose to include
these studies despite the risk of bias in order to provide
more complete information. This concern was assessed
through subgroup analysis, and key results are presented
stratified by study design. We could not assess the
potential influence of other factors that may have
influenced the overall findings such as co-infections
and concomitant prophylaxis, backbone ART regimen,
hepatitis co-infection or differences in laboratoryhorized reproduction of this article is prohibited.
Co
1142 AIDS 2013, Vol 27 No 7monitoring as these variables were not consistently
reported. Another potential concern relates to the
differences in adverse event grading systems used by
different studies; however, these systems do not differ
importantly in their grading of severity of hepatic and
cutaneous adverse events. The evidence of adverse event
risk according to low and high CD4 cell counts is based
on study-level stratification of patients into two groups,
with the result that all CD4 cell counts above 250 cells/ml
are treated equally. A more nuanced investigation of
adverse event risk at higher CD4 cell count would require
individual patient-level data, which was not available for
this review. Publication bias is an ever present concern for
systematic reviews. This was not formally assessed due to
the limited number of studies included in the review.
Finally, the relatively limited number of patients and low
event rate associated with all outcomes means that all data
are fragile and the overall quality of evidence is very low.
This review points to several directions for future
research. First, the potential association between NVP
toxicity and later-stage pregnancy noted in subgroup
analysis deserves further investigation. Second, not all
severe adverse events led to treatment discontinuations,
with up to 20% of patients in some studies continuing
NVP despite experiencing severe hepatotoxicity; the
reasons for this should be better understood in future
studies. Finally, an individual patient data meta-analysis
would allow a more precise determination of the
association between adverse event risk at higher CD4
cell count.
In conclusion, the findings of this review suggest that
there is little evidence to justify discrimination according
to pregnancy status when using NVP as part of
combination ART. An increased risk of rash among
pregnant women at higher CD4 cell count is suggested
but evidence for such an association remains very weak
and this concern needs to be weighed against the limited
adverse event monitoring capacity in many high-burden
settings. The frequency of occurrence of adverse events
associated with NVP in general suggests that, when
possible, the use of alternative drugs with better overall
toxicity profiles such as efavirenz should be considered
[33]. Such considerations are all the more important in
resource-limited settings in which capacity for toxicity
monitoring remains limited.Acknowledgements
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